ingle or multiple brief periods of coronary artery S occlusion interspersed with reperfusion have been shown to produce reversible ischemiareperfusion injury or myocardial stunning.1-7 Although considerable effort has been expended in elucidating the mechanism of stunning following a single coronary occlusion-reperfusion protocol,4-7 less research has been done to elucidate the mechanism of stunning in a multiple-occlusion model. The observation that calcium antagonists improve the recovery of regional contractile function following repetitive episodes of ischemiareperfusion3,8 suggests a role for calcium overload during ischemia or early reperfusion, and the finding that superoxide dismutase and catalase improve functional recovery suggests a role for oxygen-derived free radicals.9 In addition, disruption of the collagen matrix also has been proposed to be partially responsible for postischemic dysfunction in the multiple-occlusion model. 10 Recently, the protective role of adenosine in myocardial reperfusion injury has received considerable attention.11 Numerous studies have shown that administration of adenosine limits myocardial infarct size and attenuates myocardial stunning in animals subjected to a single coronary artery occlusion.12-14 However, the mechanisms by which adenosine exerts its cardioprotective effects and the subtype of adenosine receptor (A1 or A2) involved are not fully understood. Therefore, the main aim of the present study was to determine whether adenosine is involved in the pathogenesis of myocardial stunning produced by multiple coronary artery occlusions and, if so, which subtype of adenosine receptor (A1 or A2) is important in its actions.
236 Circulation Vol 88, No 1 July 1993 Finally, Kirsch and coworkers'S showed that adenosine A, receptors are coupled to KATP channels in rat ventricular myocytes. Previous studies performed in our laboratory also showed that activation of KATP channels attenuates and blockade of these channels exacerbates stunning in a multiple-occlusion model. 16 Therefore, a second objective of this study was to determine whether adenosine A, receptor-mediated cardioprotection was mediated via the KATP channel. To test this hypothesis, we studied the effect of a KATP channel antagonist, glibenclamide, on the beneficial action of adenosine A, receptor stimulation.
Methods

General Preparation of Dogs
All experiments conducted in this study were in accordance with the "Position of the American Heart Association on Research minutes before injection. One milliliter of the microsphere suspension (2 to 4x 106 microspheres) was given via the left atrial catheter and flushed by 5 mL of saline.
A reference blood flow sample was drawn from the femoral artery at a constant rate of 7.1 mL/min immediately before microsphere injection. Regional myocardial tissue blood flow was measured at 2 minutes during the first and sixth occlusion periods as well at the end of the final reperfusion period. On the following day, tissue slices were sectioned into subepicardium, midmyocardium, and subendocardium of nonischemic (three pieces) and ischemic regions (five pieces). The tissue samples were weighed (0.3 to 0.8 g). Transmural pieces were obtained from the center of several transverse sections used to determine the ischemic area size and were at least 1 cm from the perfusion boundaries as indicated by patent blue dye. All samples were counted in a gamma counter (Tracer Analytic 1195, TM Analytic, Elk Grove, Ill) to determine the activity of each isotope in each sample. The activity of each isotope also was determined in the reference blood flow samples. Myocardial blood flow was calculated by using a preprogrammed computer (Apple Hie) to obtain the true activity of each isotope in individual samples, and tissue blood flow was calculated from the equation QM=QrxCm/Cr where Qm is myocardial blood flow (mL *minl *g-1), Qr is the rate of withdrawal of the reference blood flow (7.1 mL/min), C, is the activity of the reference blood flow sample (counts per minute [cpml), and Cm is the activity of the tissue sample (cpm/g). 
Myocardial Segment Shortening
Myocardial segment shortening in the ischemic and nonischemic regions was assessed by two sets of piezoelectric crystals inserted 7 to 9 mm into the subendocardium. An ultrasonic amplifier was connected to the leads of the crystals. The amplifier transforms the sound pulses from the crystals into an electrical signal that is proportional to the distance between them. The tracings were monitored with an oscilloscope (Soltec model 520), and the distance between the two crystals was measured by changes in transmission time and recorded on a polygraph. Segment length during diastole (DL) and systole (SL) was determined at the onset of isovolumetric contraction (beginning of positive dP/dt) and at peak negative dP/dt, respectively. Percent segment shortening (%SS) was calculated from the equation: %SS=(DL-SL)/DLx 100. The segment length data were normalized by using a value of 10.0 for the baseline DL.
Criteria for Exclusions
Dogs were excluded if subendocardial collateral flow was more than 0.15 mL* min' * g-'), ventricular fibrillation occurred, heart rate was more than 160 beats per minute, or heartworms were found after dogs were killed.
Statistical Analysis
All values are given as the mean±SEM. A two-way ANOVA with Fisher's least significant difference was used to compare differences between groups, and a one-way ANOVA with Dunnett's t test was used to compare differences within groups. P<.05 was considered significantly different.
Results
Exclusions
A total of 63 dogs were used in this study. Six dogs were excluded because subendocardial blood flow was more than 0.15 mL min' g`(one each in series 1, 3, 7, and 8; two in series 2), another four were excluded because of ventricular fibrillation (two in series 1, one each in series 4 and 6), and another in series 5 was excluded because heartworms were found after the heart was removed. Thus, 52 dogs were used in data analysis (n=7 for series 1 and 2; n=6 for series 3, 4, 5, 6, and 8; n=5 for series 7; and n=3 for series 9).
Body Weight, Ischemic Area, and Infarct Size Body weight, left ventricular weight, and ischemic area weight for all animals used in this study were 22.1+0.3 kg, 105.6±2.2 g, and 28.3±0.8 g, respectively, and no significant differences were found between groups. There also was no evidence for infarcted tissue in any of the animals studied by TTC staining. 23 Hemodynamics and Blood Gases Heart rate, mean aortic blood pressure, the ratepressure product, left ventricular dP/dt, and LAD blood flow were monitored throughout the experiment, and the baseline values for all series are summarized in Table 1 . Hemodynamics were not significantly affected by drug treatment except that heart rate at 2 hours of reperfusion in groups pretreated with glibenclamide and the combination of glibenclamide plus CPA was slightly higher than that observed in controls. There were no significant differences in baseline values for blood gases and pH between groups (Table 2) , and no statistically significant changes occurred throughout the experiment.
Regional Myocardial Blood Flow
Regional myocardial blood flow data in the ischemic (LAD) and nonischemic (left circumflex) regions are shown in Table 3 . There were no significant differences between groups in blood flow to any layers of the ischemic myocardium. These data indicate that all groups of animals were subjected to equal degrees of Values are given as mean±SEM. There were no significant differences among groups. ischemia throughout the six occlusion periods. In the nonischemic region, blood flow was significantly lower in the glibenclamide-pretreated group, the CPA-pretreated group, and the group in which DPCPX was given after the first occlusion compared with that in the control group.
Segment Function Six 5-minute periods of coronary artery occlusion interspersed by 10-minute periods of reperfusion and finally followed by 2 hours of reperfusion produced a marked loss of myocardial segment function throughout each reperfusion period compared with the baseline control value (Figs 2 to 4 control series). Pretreatment with DPCPX dramatically worsened the recovery of percent segment shortening throughout each reperfusion period compared with the control series (Fig 2A) . However, no effects on stunning were observed when DPCPX was given 2 minutes before the second occlusion period (Fig 2B) or 1 hour after the sixth occlusion. On the other hand, pretreatment with CPA significantly attenuated myocardial stunning during all periods of reperfusion ( Fig 3A) ; however, CPA had no effect on stunning when given 2 minutes before the second occlusion (Fig 3B) . In addition, pretreatment with CGS 21680 had no effect on segment function (data not shown). Finally, glibenclamide by itself did not affect percent segment shortening ( Fig 4A) ; however, it completely abolished the beneficial effect of CPA (Fig 4B) Initially, we observed that six brief, consecutive ischemia-reperfusion cycles produced regional contractile dysfunction primarily following the first occlusion period but to a much lesser extent following the subsequent five occlusion periods. These results agree with the findings of other investigators2,25 who also have shown that the largest decrease in contractile function occurs after the initial occlusion period and that additional decrements in contractility appeared to be progressively smaller. These observations suggest that an endogenous adaptive mechanism(s) may exist in the heart that is turned on during the first brief occlusion period. Adenosine, a metabolite of adenine nucleotides, is released from the heart during ischemia,'6"7 and activation of adenosine A, or A2 receptors has been shown to ameliorate irreversible ischemia-reperfusion injury in an infarct model.21"28 More recently, Bunch et al29 proposed that endogenously released adenosine acted to preserve wall motion in a repetitive coronary artery occlusion model. Thus, it seems reasonable to hypothesize that endogenous adenosine released during the initial coronary occlusion period may activate adenosine A, receptors in the ischemic myocardium, thus rendering the myocardium resistant to subsequent ischemic insults. That the decrease in percent segment shortening during reperfusion following occlusion periods 2 to 6 was much less than that observed after occlusion period 1 and that either DPCPX or CPA given before occlusion period 2 had no effect on the recovery of percent segment shortening support this hypothesis.
Evidence that the A, receptor mediates the protective effect of adenosine in this model was obtained by the use of DPCPX, a xanthine derivative that has been demonstrated to be 700-fold selective for the adenosine A, receptor versus the A2 receptor using radioligand binding techniques and in vitro functional assays. 17 We found that DPCPX worsened the recovery of myocardial segment function throughout reperfusion in the 1) (o---o) An interesting finding in the current study was that pretreatment with a low dose of glibenclamide (0.1 mg/kg) that had no effect on percent segment shortening by itself completely abolished the protective effect of CPA. Although it might be expected that 0.1 mg/kg glibenclamide alone would worsen the recovery of percent segment shortening in a manner similar to DPCPX by blocking the beneficial effect of endogenous adenosine, this was not the case. The reason for the lack of effect of this low dose of glibenclamide is not clear; however, because it usually is more difficult to block the effects of endogenously released hormones and neurotransmitters than exogenously administered substances, it seems likely that the low dose of glibenclamide was just above some critical threshold that was effective only at antagonizing the effects of exogenously administered CPA. Nevertheless, because the protective effect of adenosine A1 receptor activation was prevented by glibenclamide, there is in vivo evidence that adenosine A1 receptors interact with KATP channels in the canine myocardium. These results are in agreement with recent results from our laboratory in which it was found that glibenclamide antagonized the infarct-reducing effect of intracoronary adenosine.43 Obviously, further studies are needed to elucidate the mechanism by which adenosine A1 receptors interact with KATP channels to protect the ischemic myocardium.
In conclusion, the present study suggests that 1) endogenously released adenosine, particularly during the initial brief period of coronary artery occlusion, plays a crucial role in the pathogenesis of myocardial stunning and may be an important endogenous mechanism that provides a cardioprotective effect during repetitive, brief episodes of myocardial ischemia; 2) the beneficial actions of adenosine are mediated via adenosine A1 receptor activation; and 3) an interaction between adenosine A1 receptor activation and a glibenclamide-sensitive mechanism exists in the canine myocardium. That an endogenous protective mechanism is linked to stimulation of adenosine A1 receptors in the heart suggests that the development of pharmacological agents that act selectively on this receptor may have great promise as myocardial protective agents for clinical applications.
